Chiral plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine and its phase i and II metabolites following controlled administration to humans

Drug Metabolism and Disposition

Volumn 43, Issue 12, 2015, Pages 1864-1871

  Steuer, Andrea E ^a   Schmidhauser, Corina ^a   Schmid, Yasmin ^b   Rickli, Anna ^b   Liechti, Matthias E ^b   Kraemer, Thomas ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIHYDROXYMETHAMPHETAMINE SULFATE; 3,4 METHYLENEDIOXYAMPHETAMINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 HYDROXY 3 METHOXYMETHAMPHETAMINE GLUCURONIDE; AMPHETAMINE DERIVATIVE; UNCLASSIFIED DRUG; 4-HYDROXY-3-METHOXYMETHAMPHETAMINE; METHAMPHETAMINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DERIVATIZATION; FEMALE; GLUCURONIDATION; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; METABOLISM; NORMAL HUMAN; PRIORITY JOURNAL; STEREOCHEMISTRY; STEREOISOMERISM; SULFATION; TANDEM MASS SPECTROMETRY; ANALOGS AND DERIVATIVES; BLOOD; CHEMISTRY; CONTROLLED CLINICAL TRIAL; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; ORAL DRUG ADMINISTRATION; YOUNG ADULT;

3,4-METHYLENEDIOXYAMPHETAMINE; ADMINISTRATION, ORAL; ADULT; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; METHAMPHETAMINE; STEREOISOMERISM; YOUNG ADULT;

EID: 84948982415     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.115.066340     Document Type: Article

References (47)

1. Antolino-Lobo I, Meulenbelt J, Nijmeijer SM, Scherpenisse P, van den Berg M, and van Duursen MBM (2010) Differential roles of phase I and phase II enzymes in 3,4-methylendioxymethamphetamineinduced cytotoxicity. Drug Metab Dispos 38:1105-1112.
2. Bai F, Lau SS, and Monks TJ (1999) Glutathione and N-acetylcysteine conjugates of alphamethyldopamine produce serotonergic neurotoxicity: possible role in methylenedioxyamphetaminemediated neurotoxicity. Chem Res Toxicol 12:1150-1157.
3. Capela JP, Carmo H, Remião F, Bastos ML, Meisel A, and Carvalho F (2009) Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview. Mol Neurobiol 39: 210-271.
4. Carvalho M, Carmo H, Costa VM, Capela JP, Pontes H, Remião F, Carvalho F, and Bastos MdeL (2012) Toxicity of amphetamines: an update. Arch Toxicol 86:1167-1231.
5. Clauwaert KM, Van Bocxlaer JF, and De Leenheer AP (2001) Stability study of the designer drugs "MDA, MDMA and MDEA" in water, serum, whole blood, and urine under various storage temperatures. Forensic Sci Int 124:36-42.
6. de la Torre R, Farré M, Ortuño J, Mas M, Brenneisen R, Roset PN, Segura J, and Camí J (2000a) Non-linear pharmacokinetics of MDMA ('ecstasy') in humans. Br J Clin Pharmacol 49: 104-109.
7. de la Torre R, Farré M, Roset PN, Lopez CH, Mas M, Ortuño J, Menoyo E, Pizarro N, Segura J, and Cami J (2000b) Pharmacology of MDMA in humans. Ann N Y Acad Sci 914:225-237.
8. de la Torre R, Farré M, Roset PN, Pizarro N, Abanades S, Segura M, Segura J, and Camí J (2004) Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. review Ther Drug Monit 26:137-144.
9. Easton N and Marsden CA (2006) Ecstasy: are animal data consistent between species and can they translate to humans? review J Psychopharmacol 20:194-210.
10. Fallon JK, Kicman AT, Henry JA, Milligan PJ, Cowan DA, and Hutt AJ (1999) Stereospecific analysis and enantiomeric disposition of 3, 4-methylenedioxymethamphetamine (Ecstasy) in humans. Clin Chem 45:1058-1069.
11. Farre M, Tomillero A, Perez-Mana C, Yubero S, Papaseit E, Roset PN, Pujadas M, Torrens M, Cami J, and de la Torre R (2015) Human pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) after repeated doses taken 4h apart Human pharmacology of MDMA after repeated doses taken 4h apart. Eur Neuropsychopharmacol DOI: 10.1016/j.euroneuro.2015.05.007. [published ahead of print].
12. Felim A, Herrera G, Neudörffer A, Blanco M, O'Connor JE, and Largeron M (2010) Synthesis and in vitro cytotoxicity profile of the R-enantiomer of 3,4-dihydroxymethamphetamine (R-(-)-HHMA): comparison with related catecholamines. Chem Res Toxicol 23:211-219.
13. Guillemette C (2003) Pharmacogenomics of human UDP-glucuronosyltransferase enzymes. Pharmacogenomics J 3:136-158.
14. Helmlin HJ, Bracher K, Bourquin D, Vonlanthen D, and Brenneisen R (1996) Analysis of 3,4-methylenedioxymethamphetamine (MDMA) and its metabolites in plasma and urine by HPLC-DAD and GC-MS. see comments J Anal Toxicol 20:432-440.
15. Hiramatsu M, Kumagai Y, Unger SE, and Cho AK (1990) Metabolism of methylenedioxymethamphetamine: formation of dihydroxymethamphetamine and a quinone identified as its glutathione adduct. J Pharmacol Exp Ther 254:521-527.
16. Hysek CM, Simmler LD, Nicola VG, Vischer N, Donzelli M, Krähenbühl S, Grouzmann E, Huwyler J, Hoener MC, and Liechti ME (2012) Duloxetine inhibits effects of MDMA ("ecstasy") in vitro and in humans in a randomized placebo-controlled laboratory study. PLoS One 7:e36476.
17. Hysek CM, Schmid Y, Simmler LD, Domes G, Heinrichs M, Eisenegger C, Preller KH, Quednow BB, and Liechti ME (2014) MDMA enhances emotional empathy and prosocial behavior. Soc Cogn Affect Neurosci 9:1645-1652.
18. Kalant H (2001) The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs. review CMAJ 165:917-928.
19. Kolbrich EA, Goodwin RS, Gorelick DA, Hayes RJ, Stein EA, and Huestis MA (2008) Plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults. Ther Drug Monit 30:320-332.
20. Kraemer T and Maurer HH (2002) Toxicokinetics of amphetamines: metabolism and toxicokinetic data of designer drugs, amphetamine, methamphetamine, and their N-alkyl derivatives. review Ther Drug Monit 24:277-289.
21. Liechti ME, Geyer MA, Hell D, and Vollenweider FX (2001) Effects of MDMA (ecstasy) on prepulse inhibition and habituation of startle in humans after pretreatment with citalopram, haloperidol, or ketanserin. Neuropsychopharmacology 24:240-252.
22. Martinez CM, Neudörffer A, and Largeron M (2012) A convenient biomimetic synthesis of optically active putative neurotoxic metabolites of MDMA ("ecstasy") from R-(-)- and S-(+)-N-methyl-a-methyldopamine precursors. Org Biomol Chem 10:3739-3748.
23. Maurer HH (1996) On the metabolism and the toxicological analysis of methylenedioxyphenylalkylamine designer drugs by gas chromatography-mass spectrometry. Ther Drug Monit 18:465-470.
24. Maurer HH, Bickeboeller-Friedrich J, Kraemer T, and Peters FT (2000) Toxicokinetics and analytical toxicology of amphetamine-derived designer drugs ('Ecstasy'). Toxicol Lett 112-113:133-142.
25. McCann UD, Szabo Z, Vranesic M, Palermo M, Mathews WB, Ravert HT, Dannals RF, and Ricaurte GA (2008) Positron emission tomographic studies of brain dopamine and serotonin transporters in abstinent (+/-)3,4-methylenedioxymethamphetamine ("ecstasy") users: relationship to cognitive performance. Psychopharmacology (Berl) 200:439-450.
26. Meyer MR and Maurer HH (2009) Enantioselectivity in the methylation of the catecholic phase I metabolites of methylenedioxy designer drugs and their capability to inhibit catechol-Omethyltransferase-catalyzed dopamine 3-methylation. Chem Res Toxicol 22:1205-1211.
27. Meyer MR, Peters FT, and Maurer HH (2008) The role of human hepatic cytochrome P450 isozymes in the metabolism of racemic 3,4-methylenedioxy-methamphetamine and its enantiomers. Drug Metab Dispos 36:2345-2354.
28. Miller RT, Lau SS, and Monks TJ (1997) 2,5-Bis-(glutathion-S-yl)-alpha-methyldopamine, a putative metabolite of (+/-)-3,4-methylenedioxyamphetamine, decreases brain serotonin concentrations. Eur J Pharmacol 323:173-180.
29. Monks TJ, Jones DC, Bai F, and Lau SS (2004) The role of metabolism in 3,4-(+)-methylenedioxyamphetamine and 3,4-(+)-methylenedioxymethamphetamine (ecstasy) toxicity. review Ther Drug Monit 26:132-136.
30. Mueller M, Yuan J, Felim A, Neudörffer A, Peters FT, Maurer HH, McCann UD, Largeron M, and Ricaurte GA (2009) Further studies on the role of metabolites in (+/-)-3,4-methylenedioxymethamphetamine-induced serotonergic neurotoxicity. Drug Metab Dispos 37: 2079-2086.
31. Peters FT, Samyn N, Kraemer T, de Boeck G, and Maurer HH (2003) Enantioselective determination of amphetamine, methamphetamine, MDA and MDMA in plasma samples from clinical toxicology and driving under the influence of drugs cases using GC-NICI-MS. abstract Ther Drug Monit 25:539.
32. Peters FT, Samyn N, Lamers C, Riedel W, Kraemer T, de Boeck G, and Maurer HH (2005) Drug testing in blood: validated negative-ion chemical ionization gas chromatographic-mass spectrometric assay for enantioselective measurement of the designer drugs MDEA, MDMA, and MDA and its application to samples from a controlled study with MDMA. Clin Chem 51: 1811-1822.
33. Pizarro N, Ortuño J, Farré M, Hernández-López C, Pujadas M, Llebaria A, Joglar J, Roset PN, Mas M, and Segura J, et al. (2002) Determination of MDMA and its metabolites in blood and urine by gas chromatography-mass spectrometry and analysis of enantiomers by capillary electrophoresis. J Anal Toxicol 26:157-165.
34. Pizarro N, Farré M, Pujadas M, Peiró AM, Roset PN, Joglar J, and de la Torre R (2004) Stereochemical analysis of 3,4-methylenedioxymethamphetamine and its main metabolites in human samples including the catechol-type metabolite (3,4-dihydroxymethamphetamine). Drug Metab Dispos 32:1001-1007.
35. Pizarro N, Ortuño J, Farré M, Hernández-López C, Pujadas M, Llebaria A, Joglar J, Roset PN, Mas M, and Segura J, et al. (2002) Determination of MDMA and its metabolites in blood and urine by gas chromatography-mass spectrometry and analysis of enantiomers by capillary electrophoresis. J Anal Toxicol 26:157-165.
36. Rietjens SJ, Hondebrink L, Westerink RH, and Meulenbelt J (2012) Pharmacokinetics and pharmacodynamics of 3,4-methylenedioxymethamphetamine (MDMA): interindividual differences due to polymorphisms and drug-drug interactions. Crit Rev Toxicol 42:854-876.
37. Schindler CW, Thorndike EB, Blough BE, Tella SR, Goldberg SR, and Baumann MH (2014) Effects of 3,4-methylenedioxymethamphetamine (MDMA) and its main metabolites on cardiovascular function in conscious rats. Br J Pharmacol 171:83-91.
38. Schmid Y, Rickli A, Schaffner A, Duthaler U, Grouzmann E, Hysek CM, and Liechti ME (2015) Interactions between bupropion and 3,4-methylenedioxymethamphetamine in healthy subjects. J Pharmacol Exp Ther 353:102-111.
39. Schwaninger AE, Meyer MR, Zapp J, and Maurer HH (2009) The role of human UDPglucuronyltransferases on the formation of the methylenedioxymethamphetamine (ecstasy) phase II metabolites R- and S-3-methoxymethamphetamine 4-O-glucuronides. Drug Metab Dispos 37:2212-2220.
40. Schwaninger AE, Meyer MR, Barnes AJ, Kolbrich-Spargo EA, Gorelick DA, Goodwin RS, Huestis MA, and Maurer HH (2011a) Urinary excretion kinetics of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and its phase I and phase II metabolites in humans following controlled MDMA administration. Clin Chem 57:1748-1756.
41. Schwaninger AE, Meyer MR, and Maurer HH (2011b) Investigation on the enantioselectivity of the sulfation of the methylenedioxymethamphetamine metabolites 3,4-dihydroxymethamphetamine and 4-hydroxy-3-methoxymethamphetamine using the substrate-depletion approach. Drug Metab Dispos 39:1998-2002.
42. Schwaninger AE, Meyer MR, Zapp J, and Maurer HH (2011c) Sulfation of the 3,4-methylenedioxymethamphetamine (MDMA) metabolites 3,4-dihydroxymethamphetamine (DHMA) and 4-hydroxy-3-methoxymethamphetamine (HMMA) and their capability to inhibit human sulfotransferases. Toxicol Lett 202:120-128.
43. Schwaninger AE, Meyer MR, Barnes AJ, Kolbrich-Spargo EA, Gorelick DA, Goodwin RS, Huestis MA, and Maurer HH (2012) Stereoselective urinary MDMA (ecstasy) and metabolites excretion kinetics following controlled MDMA administration to humans. Biochem Pharmacol 83:131-138.
44. Segura M, Ortuño J, Farré M, McLure JA, Pujadas M, Pizarro N, Llebaria A, Joglar J, Roset PN, and Segura J, et al. (2001) 3,4-Dihydroxymethamphetamine (HHMA). A major in vivo 3,4-methylenedioxymethamphetamine (MDMA) metabolite in humans. Chem Res Toxicol 14: 1203-1208.
45. Shen M, Xiang P, Sun Y, and Shen B (2013) Disappearance of 6-acetylmorphine, morphine and codeine from human scalp hair after discontinuation of opiate abuse. Forensic Sci Int 227: 64-68.
46. Shoda T, Fukuhara K, Goda Y, and Okuda H (2009) 4-Hydroxy-3-methoxymethamphetamine glucuronide as a phase II metabolite of 3,4-methylenedioxymethamphetamine: enzyme-assisted synthesis and involvement of human hepatic uridine 59-diphosphate-glucuronosyltransferase 2B15 in the glucuronidation. Chem Pharm Bull (Tokyo) 57:472-475.
47. Steuer AE, Schmidhauser C, Liechti ME, and Kraemer T (2015) Development and validation of an LC-MS/MS method after chiral derivatization for the simultaneous stereoselective determination of methylenedioxy-methamphetamine (MDMA) and its phase I and II metabolites in human blood plasma. Drug Test Anal 7:592-602.